Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.

被引：0
|
作者：
Xu, Yongkang [1 ]
Fu, Shumin [1 ]
Mao, Ye [1 ]
Yi, Fengming [1 ]
Jiang, Weiming [1 ]
Feng, Long [1 ]
Wu, Jianbing [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
298-145-222-184-4809-5347; 281-5277-2622-5397; 281-5277-6771; 261-492-2769; 3282-3306-3348-4026; 283-2494; 613-135-244-3829-325; 3; 2; 28; 2424; 54; 239; 193; 1700; 4; 1; 38092-32104; 38116-38094-8;
D O I：
10.1200/JCO.2024.42.3_suppl.500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：500 / 500
页数：1
相关论文
共 50 条
  • [31] TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
    Liu, S.
    Lin, S.
    Luo, H.
    Luo, J.
    Mo, W.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S78 - S79
  • [32] Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study
    Zhang, Zhibo
    Yan, Maolin
    Chen, Yufeng
    Wu, Xukun
    Yang, Lanfang
    Yin, Zhengyu
    Lu, Hao
    Zeng, Yongyi
    Zhang, Hui
    Huang, Jingyao
    Chen, Jiafei
    Wang, Liang
    Chen, Zhongwu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial
    Zhou, X.
    Zhu, H.
    Gao, H.
    Niu, Z.
    Liu, M.
    Wang, H.
    Kong, X.
    Ma, C.
    Yang, F.
    Hao, Y.
    Zhang, S.
    Lu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1489 - S1489
  • [34] Hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with lenvatinib for first-line treatment of unresectable HCC: A prospective, single arm, phase II study (HAITC study)
    Yu, H.
    Xu, Y.
    Xing, W.
    Guo, Z.
    Liu, C.
    Gao, W.
    Xueling, Y.
    Zhang, W.
    Li, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1481 - S1482
  • [35] Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.
    Liu, Qu
    Chang, Zhengyu
    Zhao, Guodong
    Gao, Yuanxing
    Tan, Xianglong
    Zhang, Xuan
    Jin, Hailong
    Liu, Rong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial
    Chen, Zhiyu
    Zhang, Leida
    Zhang, Hui
    Gong, Yi
    Feng, Kai
    Ma, Kuansheng
    Bi, Huaqiang
    Xia, Feng
    Dai, Haisu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
    Xu, Yu-Jie
    Lai, Zhi-Cheng
    He, Min-Ke
    Bu, Xiao-Yun
    Chen, Huan-Wei
    Zhou, Yuan-Min
    Xu, Li
    Wei, Wei
    Zhang, Yao-Jun
    Chen, Min-Shan
    Guo, Rong-Ping
    Shi, Ming
    Li, Qi-Jiong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [38] A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.
    Li, Xiaowei
    Cao, Kunkun
    Fu, Zhigang
    Zhong, Jiaming
    Liu, Li
    Chen, Xiaoxia
    Ding, Ning
    Zhang, Xiaoli
    Qu, Zengqiang
    Zhai, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial infusion chemotherapy (HAIC) for unresectable biliary tract cancer
    Cai, H.
    Tang, S.
    Guo, W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1478 - S1479
  • [40] Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
    Wu, Xu-Kun
    Yang, Lan-Fang
    Chen, Yu-Feng
    Chen, Zhong-Wu
    Lu, Hao
    Shen, Xue-Yi
    Chi, Min-Hui
    Wang, Liang
    Zhang, Hui
    Chen, Jia-Fei
    Huang, Jing-Yao
    Zeng, Yong-Yi
    Yan, Mao-Lin
    Zhang, Zhi-Bo
    ECLINICALMEDICINE, 2024, 67
12345